FindTrial
Sign In

STREPTOZOTOCINE + MITOTANE IN THE TREATMENT OF ADRENO-CORTICAL CANCER PATIENTS PROGRESSED AFTER CHEMOTHERAPY WITH CISPLATIN CONTAINING SCHEME

STREPTOZOTOCINE + MITOTANE IN THE TREATMENT OF ADRENO-CORTICAL CANCER PATIENTS PROGRESSED AFTER CHEMOTHERAPY WITH CISPLATIN CONTAINING SCHEME

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-004354-27-IT
Enrollment
Unknown
Registered
2005-09-19
Start date
2005-07-13
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy in patients with locally advanced or metastatic adrenocortical cancer MedDRA version: 6.1 Level: PT Classification code 10007284

Interventions

Product Name: NA Product Code: NA Pharmaceutical Form: Powder for infusion* INN or Proposed INN: Streptozocin Concentration unit: g gram(s) Concentration type: equal Concentration number: 1- Product

Sponsors

AZIENDA OSPEDALIERA S. LUIGI GONZAGA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026